通过分子建模方法发现新的针对PPAR-γ和α-葡萄糖酶的双重向剂:分子对接,分子动态模拟和MM/PBSA分析
Süleyman Kaya1, Gizem Tatar-Yılmaz2, Bedriye Seda Kurşun Aktar3
1Department of Biostatistics and Medical Informatics, Faculty of Medicine, Karadeniz Technical University, Trabzon, Turkey.
The protein journal
|April 20, 2024
概括
使用分子建模设计了新的双目标抗糖尿病药物. 化合物70有效向PPAR-γ和α-葡萄糖酶,显示了改善2型糖尿病治疗的前景,副作用更少.
科学领域:
- 药用化学 医学化学
- 计算化学计算化学
- 药理学 药理学是指药理学的学科.
背景情况:
- 2型糖尿病 (T2DM) 是一个全球性的健康问题,目前的组合疗法造成了显著的副作用和成本.
- 与氧酶增殖器激活受体-γ (PPAR-γ) 和α-葡萄糖酶 (α-葡萄糖酶) 相互作用的双目标药物为T2DM提供了有前途的治疗策略.
- 开发具有提高疗效和减少副作用的新型抗糖尿病药物至关重要.
研究的目的:
- 使用分子建模设计和识别PPAR-γ和α-葡萄糖酶的新型双抗糖尿病药物.
- 为了评估设计化合物的结合相互作用,ADME特性和药理动力学适用性.
- 发现有潜力提高T2DM治疗效率和安全性的强效化合物.
主要方法:
- 用分子对接来评估159种针对PPAR-γ和α-葡萄糖酶的设计化合物的酶-连接物相互作用.
- 使用Lipinski和Veber的规则来评估ADME的特性和药理动力学适用性.
- 对化合物进行了MM/PBSA结合的自由能量和分子动力学 (MD) 模拟.
主要成果:
- 与参考药物相比,化合物70与PPAR-γ (-12.16 kcal/mol) 和α-葡萄糖酶 (-10.07 kcal/mol) 显示出更高的结合能.
- 化合物70表现出有利的ADME特性和药理动力学特征.
- MM/PBSA和MD模拟证实了70化合物与两个向酶的强烈结合亲和关系.
结论:
- 设计的化合物70显示出作为T2DM的双抗糖尿病剂的显著潜力.
- 这种方法为开发更有效,更安全的糖尿病治疗提供了战略.
- 对70化合物的进一步研究和开发可能会为T2DM患者带来更好的治疗选择.
相关概念视频
Glucagon-like Receptor Agonists
319
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
319
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
174
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
Acarbose and miglitol are...
174
Dipeptidyl Peptidase 4 Inhibitors
182
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
182
Oral Hypoglycemic Agents: Glinides
154
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
154
Oral Hypoglycemic Agents: Biguanides and Glitazones
195
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
195
G Protein-coupled Receptors
11.9K
G Protein-Coupled Receptors or GPCRs are membrane-bound receptors that transiently associate with heterotrimeric G proteins and induce an appropriate response to sensory stimuli such as light, odors, hormones, cytokines, or neurotransmitters.
GPCRs are also called heptahelical, 7TM, or serpentine receptors, and consist of seven (H1-H7) transmembrane alpha-helices that span the bilayer to form a cylindrical core. The transmembrane helices are connected by three extracellular loops and three...
GPCRs are also called heptahelical, 7TM, or serpentine receptors, and consist of seven (H1-H7) transmembrane alpha-helices that span the bilayer to form a cylindrical core. The transmembrane helices are connected by three extracellular loops and three...
11.9K


